Diary

  • Mon
    11
    Jan
    2021

    9.30am - 1pmOnline, live event

     

    Please be aware that this will be a virtual event. Details to be confirmed.

     

    Description: A half-day course repeated morning and afternoon describing the theory behind the new immunotherapy treatments for cancer such as checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab), adoptive cell therapy (CAR T cell therapy, infiltrating T cells), and vaccine-based treatments (peptide and DNA vaccines, oncolytic viruses, dendritic cell vaccines).
    Level: Intermediate
    Cost: £100
    Audience: Ideal for anyone with an A level or equivalent understanding of cell biology and genetics and who works with cancer patients, data or treatments.
    To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
    View an outline of the programme

  • Tue
    02
    Feb
    2021

    Live, online event

     

    Please be aware that this will be a virtual event. Details to be confirmed.

    Description: In this study day I describe the unique cellular and genetic features of haematological cancers and covers a diverse range of targeted treatments for leukaemias, lymphomas and multiple myeloma. Treatments explained include a wide range of monoclonal antibodies, B cell receptor signalling blockers and JAK2, Bcl-2, FLT3 and CDK inhibitors. I also explore the potential of immunotherapy with checkpoint inhibitors and CAR T cells.
    Level: Intermediate/Advanced
    Audience:Ideal for pharmacists, research nurses, people from pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.
    Cost: £150
    To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
    View an outline of the programme